Trials / Completed
CompletedNCT03118531
China Resolute Integrity 34/38 mm Study
Evaluation of the Clinical Safety and Efficacy of the 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Subjects According to the Indication for Use.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Medtronic Vascular · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the clinical safety and efficacy in Chinese subjects, eligible for percutaneous transluminal coronary angioplasty (PTCA) in lesions amenable to treatment with a 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System.
Conditions
- Ischemic Heart Disease
- Stenotic Coronary Lesion
- Cardiovascular Diseases
- Arteriosclerosis
- Coronary Artery Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm) | The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent. |
Timeline
- Start date
- 2017-04-17
- Primary completion
- 2018-07-31
- Completion
- 2023-04-28
- First posted
- 2017-04-18
- Last updated
- 2023-10-10
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03118531. Inclusion in this directory is not an endorsement.